NASDAQ: IINNInspira Technologies Oxy Bhn Ltd Stock
$1.30-0.04 (-2.99%)
Updated Dec 4, 2024
IINN Price
$1.30
Fair Value Price
$0.34
Market Cap
$23.88M
52 Week Low
$0.76
52 Week High
$2.49
P/E
-1.68x
P/B
4.47x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.76
Operating Cash Flow
-$10M
Beta
1.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IINN Overview
Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company developing respiratory support technologies as alternatives to invasive mechanical ventilation for the treatment of respiratory failure. The company's augmented respiration technology system is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. Inspira was incorporated in 2018 and is headquartered in Ra'annana, IL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IINN's potential to beat the market
- IINN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important IINN news, forecast changes, insider trades & much more!
IINN News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IINN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IINN ($1.30) is overvalued by 276.26% relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IINN ($1.30) is not significantly undervalued (276.26%) relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IINN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IINN due diligence checks available for Premium users.
Valuation
IINN fair value
Fair Value of IINN stock based on Discounted Cash Flow (DCF)
Price
$1.30
Fair Value
$0.34
Overvalued by
277.71%
IINN ($1.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IINN ($1.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IINN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IINN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.68x
Industry
37.49x
Market
28.79x
IINN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.47x
Industry
4.1x
IINN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IINN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
IINN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.4M
Liabilities
$4.1M
Debt to equity
0.76
IINN's short-term assets ($8.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IINN's short-term assets ($8.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IINN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
IINN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IINN vs Medical Device Stocks
Inspira Technologies Oxy Bhn Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.